Anzeige
Mehr »
Lynx Broker
Login
Montag, 19.08.2019 Börsentäglich über 12.000 News von 605 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Zur alten Webversion

WKN: 885823 ISIN: US3755581036 Ticker-Symbol: GIS 
Xetra
16.08.19
17:35 Uhr
57,06 Euro
-0,14
-0,24 %
1-Jahres-Chart
GILEAD SCIENCES INC Chart 1 Jahr
5-Tage-Chart
GILEAD SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
56,76
57,10
18.08.
56,83
56,95
16.08.

Aktuelle News zur GILEAD SCIENCES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
GILEAD SCIENCES Aktien ab 5,00 US-Dollar handeln - Ohne versteckte Kosten!
MiIs Gilead Sciences (GILD) a Great Stock for Value Investors?55
12.08.Gilead Chugs Along44
12.08.3 Big Stock Charts for Monday: Xilinx, News Corp and Gilead Sciences24
09.08.Gilead's HIV drug Biktarvy approved in China28
08.08.Is Gilead Stock A Buy Right Now? Here's What Earnings, Chart Show45
08.08.Agenus, Gilead Milestone Triggers $7.5M Payment14
08.08.The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering30
08.08.FDA AdCom backs Gilead's move to expand Descovy label - but stops short of endorsing broad PrEP use4
08.08.Dermira On Watchlist, FDA Panel Nod For GILD, So Long, CVRS And AVDR72FOSTER CITY (dpa-AFX) - Today's Daily Dose brings you news about the acquisition of Corindus and Avedro; FDA panel recommending approval of Gilead's Descovy; and stellar results of Hanger...
► Artikel lesen
08.08.Gilead's Descovy AdCom gets 'controversial' as panelists split over PrEP use in women5
08.08.Gilead Sciences Statement on U.S. Food and Drug Administration Advisory Committee's Recommendation on Descovy for PrEP103Gilead Sciences, Inc. (NASDAQ: GILD)announced today that theAntimicrobial Drugs Advisory Committee (AMDAC) of the U.S. Food and Drug Administration (FDA) recommended approval of Descovy (emtricitabine...
► Artikel lesen
07.08.UPDATE 1-FDA panel backs Gilead's HIV prevention drug Descovy, except in women5
07.08.FDA panel backs Gilead's HIV prevention drug for certain population3
07.08.FDA advisory committee backs Gilead's Descovy for PrEP3
07.08.Former Gilead CSO McHutchison takes charge at Assembly Biosciences3
07.08.Gilead's newly departed R&D chief re-emerges as CEO of a rival biotech looking to make a comeback14
07.08.FOCUS-Patient groups push back against Gilead's pricey HIV prevention treatment11
06.08.GILEAD SCIENCES INC - 10-Q, Quaterly Report22
06.08.Gilead's Descovy seems set for a PrEP nod in men, FDA review shows. But what about women?12
06.08.Gilead faces a hurdle in its race for big, add-on OK for Descovy as generic Truvada rivals loom11
Seite:  Weiter >>
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
21,13,101